SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Genentech Inc – ‘S-4/A’ on 9/8/95 – EX-23.3

As of:  Friday, 9/8/95   ·   Accession #:  950123-95-2577   ·   File #:  33-59949

Previous ‘S-4’:  ‘S-4’ on 6/5/95   ·   Next:  ‘S-4/A’ on 9/18/95   ·   Latest:  ‘S-4/A’ on 10/18/05

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 9/08/95  Genentech Inc                     S-4/A                 13:801K                                   RR Donnelley/FA

Pre-Effective Amendment to Registration of Securities Issued in a Business-Combination Transaction   —   Form S-4
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Amendement No.1 to Form S-4                          189   1.10M 
 2: EX-2.2      Agreement, Dated as of July 7, 1995                    7     25K 
 3: EX-2.3      Agreement, Dated as of September 6, 1995              12     40K 
 4: EX-5.1      Opinion of Wachtell, Lipton, Rosen                     2     10K 
 5: EX-8.1      Opinion of Wachtell, Lipton, Rosen                     1      9K 
 6: EX-10.4     Agency Agreement, Dated as of September 6, 1995       12     39K 
 7: EX-10.5     Letter Agreement, Dated September 6, 1995              2     12K 
 8: EX-15.1     Letter Re: Unaudited Interim Financial Information     1      8K 
 9: EX-23.2     Consent of Ernst & Young LLP                           1      8K 
10: EX-23.3     Consent of Price Waterhouse Ag                         1      6K 
11: EX-24.1     Powers of Attorneys                                    1      9K 
12: EX-27.1     Financial Data Schedule                                1     10K 
13: EX-99.1     Form of Proxy for Special Meeting of Stockholders      2±    11K 


EX-23.3   —   Consent of Price Waterhouse Ag

EX-23.3TOCTopPreviousNextBottomJust 1st
 

Exhibit 23.3 Consent of Roche Group Auditors We hereby consent to the use in the Proxy Statement/Prospectus of Genentech Inc. of our report dated 27 April 1995 which appears in such Proxy Statement/ Prospectus and relates to the consolidated financial statements of the Roche Group which have been extracted from the 1994 Annual Report. We also consent to the reference to us under the heading "Experts" in such Proxy Statement/ Prospectus. Price Waterhouse AG Jack W. Flamson Ralph R. Reinertsen Certified Public Accountant Certified Public Accountant Auditors in charge Basel, Switzerland 7 September 1995
Top
Filing Submission 0000950123-95-002577   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 12:07:15.1am ET